Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study

Alessio Giuseppe Morganti; Mariangela Massaccesi; Luciana Caravatta; Gabriella Macchia; Vincenzo Picardi; Francesco Deodato; Edy Ippolito; Samantha Mignogna; Milena Ferro; Savino Cilla; Gian Carlo Mattiucci; Vincenzo Valentini

Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study

Alessio Giuseppe Morganti
, Mariangela Massaccesi
, Luciana Caravatta
, Gabriella Macchia
, Vincenzo Picardi
, Francesco Deodato
, Edy Ippolito
, Samantha Mignogna
, Milena Ferro
, Savino Cilla
, Gian Carlo Mattiucci
, Vincenzo Valentini

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).

Lingua originale	Inglese
pagine (da-a)	4585-4589
Numero di pagine	5
Rivista	Anticancer Research
Volume	33
Stato di pubblicazione	Pubblicato - 2013

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Adenocarcinoma
Administration, Metronomic
Aged
Aged, 80 and over
Chemoradiation
Chemoradiotherapy
Disease-Free Survival
Dose Fractionation
Humans
Kaplan-Meier Estimate
Male
Prospective Studies
Prostatic Neoplasms, Castration-Resistant
Treatment Outcome
hormone-refractory prostate cancer
metronomic chemotherapy
phase I study

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{2b98f6123303412da3e49204d0eba239,

title = "Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study",

abstract = "To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).",

keywords = "Adenocarcinoma, Administration, Metronomic, Aged, Aged, 80 and over, Chemoradiation, Chemoradiotherapy, Disease-Free Survival, Dose Fractionation, Humans, Kaplan-Meier Estimate, Male, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, hormone-refractory prostate cancer, metronomic chemotherapy, phase I study, Adenocarcinoma, Administration, Metronomic, Aged, Aged, 80 and over, Chemoradiation, Chemoradiotherapy, Disease-Free Survival, Dose Fractionation, Humans, Kaplan-Meier Estimate, Male, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, hormone-refractory prostate cancer, metronomic chemotherapy, phase I study",

author = "Morganti, \{Alessio Giuseppe\} and Mariangela Massaccesi and Luciana Caravatta and Gabriella Macchia and Vincenzo Picardi and Francesco Deodato and Edy Ippolito and Samantha Mignogna and Milena Ferro and Savino Cilla and Mattiucci, \{Gian Carlo\} and Vincenzo Valentini",

year = "2013",

language = "English",

volume = "33",

pages = "4585--4589",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study

AU - Morganti, Alessio Giuseppe

AU - Massaccesi, Mariangela

AU - Caravatta, Luciana

AU - Macchia, Gabriella

AU - Picardi, Vincenzo

AU - Deodato, Francesco

AU - Ippolito, Edy

AU - Mignogna, Samantha

AU - Ferro, Milena

AU - Cilla, Savino

AU - Mattiucci, Gian Carlo

AU - Valentini, Vincenzo

PY - 2013

Y1 - 2013

N2 - To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).

AB - To determine the maximum tolerated dose of hypofractionated radiotherapy (HFRT) plus concurrent metronomic chemotherapy in patients with hormone-refractory prostate cancer (HRPC).

KW - Adenocarcinoma

KW - Administration, Metronomic

KW - Aged

KW - Aged, 80 and over

KW - Chemoradiation

KW - Chemoradiotherapy

KW - Disease-Free Survival

KW - Dose Fractionation

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Prospective Studies

KW - Prostatic Neoplasms, Castration-Resistant

KW - Treatment Outcome

KW - hormone-refractory prostate cancer

KW - metronomic chemotherapy

KW - phase I study

KW - Adenocarcinoma

KW - Administration, Metronomic

KW - Aged

KW - Aged, 80 and over

KW - Chemoradiation

KW - Chemoradiotherapy

KW - Disease-Free Survival

KW - Dose Fractionation

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Prospective Studies

KW - Prostatic Neoplasms, Castration-Resistant

KW - Treatment Outcome

KW - hormone-refractory prostate cancer

KW - metronomic chemotherapy

KW - phase I study

UR - http://hdl.handle.net/10807/51979

M3 - Article

SN - 0250-7005

VL - 33

SP - 4585

EP - 4589

JO - Anticancer Research

JF - Anticancer Research

ER -

Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study

Abstract

OSS delle Nazioni Unite

Keywords

Altri file e collegamenti

Fingerprint

Cita questo